

Kwang-Hee Shin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2833204/publications.pdf>

Version: 2024-02-01

57
papers

691
citations

623574

14
h-index

642610

23
g-index

57
all docs

57
docs citations

57
times ranked

1161
citing authors

#	ARTICLE	IF	CITATIONS
1	Signal detection for adverse event of varenicline in Korea Adverse Event Reporting System. Korean Journal of Clinical Pharmacy, 2022, 32, 1-7.	0.0	4
2	Comparison of Efficacy and Safety of Statin+Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies. American Journal of Cardiovascular Drugs, 2022, 22, 395-406.	1.0	6
3	Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intra-gastric pH Alterations. Pharmaceutics, 2022, 14, 1298.	2.0	4
4	Bioanalytical methods for the detection of duloxetine and thioctic acid in plasma using ultra performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS). Translational and Clinical Pharmacology, 2022, 30, 99.	0.3	0
5	Physiologically-based pharmacokinetic model for clozapine in Korean patients with schizophrenia. Translational and Clinical Pharmacology, 2021, 29, 33.	0.3	8
6	Effect of dipeptidyl peptidase IV inhibitors, thiazolidinedione, and sulfonylurea on osteoporosis in patients with type 2 diabetes: population-based cohort study. Osteoporosis International, 2021, 32, 1705-1712.	1.3	8
7	Urinary Metabolomic Profiling after Administration of Corydalis Tuber and Pharbitis Seed Extract in Healthy Korean Volunteers. Pharmaceutics, 2021, 13, 522.	2.0	3
8	Prediction of fluoxetine and norfluoxetine pharmacokinetic profiles using physiologically based pharmacokinetic modeling. Journal of Clinical Pharmacology, 2021, 61, 1505-1513.	1.0	0
9	Determination of candesartan or olmesartan in hypertensive patient plasma using UPLC-MS/MS. Translational and Clinical Pharmacology, 2021, 29, 226.	0.3	4
10	Signal Detection for Adverse Events of Finasteride Using Korea Adverse Event Reporting System (KAERS) Database. Korean Journal of Clinical Pharmacy, 2021, 31, 324-331.	0.0	3
11	Bioanalytical Method Using Ultra-High-Performance Liquid Chromatography Coupled with High-Resolution Mass Spectrometry (UHPL-CHRMS) for the Detection of Metformin in Human Plasma. Molecules, 2020, 25, 4625.	1.7	8
12	Quantification of apixaban in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry. Translational and Clinical Pharmacology, 2019, 27, 33.	0.3	9
13	Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6. Drug Design, Development and Therapy, 2019, Volume 13, 1751-1761.	2.0	14
14	Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and O-Desmethyltramadol Pharmacokinetic Profiles in a Korean Population Using Physiologically-Based Pharmacokinetic Modeling. Pharmaceutics, 2019, 11, 618.	2.0	4
15	Metabolite signature associated with stress susceptibility in socially defeated mice. Brain Research, 2019, 1708, 171-180.	1.1	14
16	Metabolite changes in risk of type 2 diabetes mellitus in cohort studies: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2018, 140, 216-227.	1.1	26
17	Identification of β -Hydroxylated Medium-Chain Acylcarnitines as Novel Urinary Biomarkers for CYP3A Activity. Clinical Pharmacology and Therapeutics, 2018, 103, 879-887.	2.3	10
18	Survey on the undergraduate curriculum in clinical pharmacology and interns' prescribing ability in South Korea. Translational and Clinical Pharmacology, 2018, 26, 128.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Development of a UPLC-MS/MS method for the therapeutic monitoring of L-asparaginase. <i>Translational and Clinical Pharmacology</i> , 2018, 26, 134.	0.3	5
20	A Pharmacometabolomic Approach to Predict Response to Metformin in Early-Phase Type 2 Diabetes Mellitus Patients. <i>Molecules</i> , 2018, 23, 1579.	1.7	16
21	Dose-proportional pharmacokinetic properties of GLA5PR GLARS-NF1 controlled-release pregabalin in healthy Korean volunteers: a randomized, open, single-dose, parallel study. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3449-3457.	2.0	7
22	Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 331-337.	2.0	4
23	Effect of green tea catechins on the pharmacokinetics of digoxin in humans. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2139-2147.	2.0	24
24	Quantitative Analysis of Four Catechins from Green Tea Extract in Human Plasma Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry for Pharmacokinetic Studies. <i>Molecules</i> , 2018, 23, 984.	1.7	13
25	Determination of donepezil in human plasma using ultra performance liquid chromatography-tandem mass spectrometry. <i>Translational and Clinical Pharmacology</i> , 2018, 26, 64.	0.3	3
26	Effect of Green Tea Extract on the Pharmacokinetics of Digoxin in Healthy Volunteers. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO1-11-37.	0.0	0
27	An Accelerator Mass Spectrometry-Enabled Microtracer Study to Evaluate the First-Pass Effect on the Absorption of YH4808. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 537-546.	2.3	3
28	Association of TNF-alpha G-308A gene polymorphism with depression: a meta-analysis. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2661-2668.	1.0	9
29	The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1525.	2.0	2
30	Urinary 6β -Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach. <i>AAPS Journal</i> , 2016, 18, 1254-1261.	2.2	31
31	A Detailed Analysis of Alcohol Pharmacokinetics in Healthy Korean Men. <i>Korean Journal of Legal Medicine</i> , 2015, 39, 27.	0.1	2
32	Aspirin Decreases Systemic Exposure to Clopidogrel Through Modulation of P-Glycoprotein But Does Not Alter Its Antithrombotic Activity. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 608-616.	2.3	26
33	Trough Concentration Over 12.1 mg/L is a Major Risk Factor of Vancomycin-Related Nephrotoxicity in Patients With Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 606-611.	1.0	19
34	Pharmacokinetics, Safety and Tolerability of DA-6034, an Anti-Inflammatory Agent, After Single and Multiple Oral Administrations in Healthy Volunteers. <i>Clinical Drug Investigation</i> , 2014, 34, 37-42.	1.1	3
35	An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects. <i>Investigational New Drugs</i> , 2014, 32, 636-643.	1.2	8
36	Pharmacodynamics, Pharmacokinetics, and Tolerability of Intravenous or Subcutaneous GC1113, a Novel Erythropoiesis-Stimulating Agent. <i>Clinical Drug Investigation</i> , 2014, 34, 373-382.	1.1	3

#	ARTICLE	IF	CITATIONS
37	Relationship Between Absolute Neutrophil Count Profiles and Pharmacokinetics of DA-3031, a Pegylated Granulocyte Colony-Stimulating Factor (Pegylated-G-CSF): A Dose Block-Randomized, Double-Blind, Dose-Escalation Study in Healthy Subjects. <i>Clinical Drug Investigation</i> , 2013, 33, 817-824.	1.1	8
38	Evaluation of Endogenous Metabolic Markers of Hepatic CYP3A Activity Using Metabolic Profiling and Midazolam Clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 601-609.	2.3	95
39	Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet. <i>Current Medical Research and Opinion</i> , 2013, 29, 1349-1355.	0.9	16
40	Reduced Valproic Acid Serum Concentrations Due to Drug Interactions With Carbapenem Antibiotics. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 599-603.	1.0	44
41	Assessment of the Drug-Drug Interactions Between Fimasartan and Hydrochlorothiazide in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 59, 84-91.	0.8	21
42	Assessment of the Effect of Mirodenafil on the Hemodynamics of Healthy Male Korean Volunteers Administered Tamsulosin: A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study. <i>Clinical Therapeutics</i> , 2012, 34, 1929-1939.	1.1	7
43	Compartmental modeling and simplified quantification of [¹¹ C]sertraline distribution in human brain. <i>Archives of Pharmacal Research</i> , 2012, 35, 1591-1597.	2.7	5
44	Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 17-23.	0.3	9
45	A positron emission tomography microdosing study with sertraline in healthy volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 224-232.	0.3	5
46	Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 722-728.	0.3	1
47	The Effect of the Newly Developed Angiotensin Receptor II Antagonist Fimasartan on the Pharmacokinetics of Atorvastatin in Relation to OATP1B1 in Healthy Male Volunteers. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 58, 492-499.	0.8	29
48	Tolerability and Pharmacokinetics of Lobeglitazone (CKD-501), a Peroxisome Proliferator-Activated Receptor- γ Agonist: A Single- and Multiple-Dose, Double-Blind, Randomized Control Study in Healthy Male Korean Subjects. <i>Clinical Therapeutics</i> , 2011, 33, 1819-1830.	1.1	38
49	Pharmacokinetic Comparison of a New Sustained-Release Formulation of Glimepiride/Metformin 1/500 mg Combination Tablet and a Sustained-Release Formulation of Glimepiride/Metformin 2/500 mg Combination Tablet in Healthy Korean Male Volunteers: A Randomized, 2-Sequence, 2-Period, 2-Treatment Crossover Study. <i>Clinical Therapeutics</i> , 2011, 33, 1809-1818.	1.1	7
50	Pharmacokinetic Profiles of Ceftazidime after Intravenous Administration in Patients Undergoing Automated Peritoneal Dialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2523-2527.	1.4	11
51	Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2011, 49, 672-678.	0.3	4
52	Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 307-310.	1.1	8
53	Pharmacokinetics of Intravenous Piperacillin Administration in Patients Undergoing On-Line Hemodiafiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3266-3268.	1.4	8
54	Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: A single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. <i>Clinical Therapeutics</i> , 2009, 31, 2755-2764.	1.1	10

#	ARTICLE	IF	CITATIONS
55	The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: An open-label, one-sequence, three-period, three-treatment crossover study. <i>Clinical Therapeutics</i> , 2009, 31, 3009-3020.	1.1	16
56	Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: A dose-â€”block-randomized, double-blind, placebo-controlled, ascending single-dose, phase I study. <i>Clinical Therapeutics</i> , 2008, 30, 1817-1830.	1.1	41
57	Regulation of drug transporters by microRNA and implications in disease treatment. <i>Journal of Pharmaceutical Investigation</i> , 0, , 1.	2.7	5